Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M361Revenue (TTM) $M5.9Net Margin (%)567Altman Z-Score7.2
Enterprise Value $M354EPS (TTM) $0.3Operating Margin %-995.9Piotroski F-Score3
P/E(ttm)10.2Beneish M-Score-2.4Pre-tax Margin (%)317Higher ROA y-yY
Price/Book2.910-y EBITDA Growth Rate %32.5Quick Ratio2.9Cash flow > EarningsN
Price/Sales53.45-y EBITDA Growth Rate %10.1Current Ratio2.9Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)29.5Higher Current Ratio y-yN
Dividend Yield %--PEG1.0ROE % (ttm)46.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M103ROIC % (ttm)-84.1Gross Margin Increase y-yY

Gurus Latest Trades with BTX

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

BTX is held by these investors:



BTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BROADWOOD PARTNERS, L.P.Director, 10% Owner 2017-02-15Buy2,222,222$2.718.15view
BROADWOOD PARTNERS LPDirector, 10% Owner 2016-06-21Buy2,732,636$2.3933.47view
BROADWOOD PARTNERS LPDirector, 10% Owner 2016-01-20Buy300,000$2.3535.74view
KINGSLEY ALFRED DSee Remarks, 10% Owner 2016-01-20Sell300,000$2.3535.74view
FARRELL STEPHEN CDirector 2015-11-06Buy50,000$3.83-16.71view
Russell Angus C.Director 2015-11-06Buy50,000$3.83-16.71view
KINGSLEY ALFRED DSee Remarks, 10% Owner 2015-11-06Sell100,000$3.83-16.71view
ANDREWS DEBORAH JDirector 2015-08-26Buy2,000$2.8213.12view
Cartt Stephen LaHueDirector 2015-08-18Buy75,000$2.813.93view
Russell Angus C.Director 2014-12-12Sell0$013.93view

Quarterly/Annual Reports about BTX:

News about BTX:

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

More From Other Websites
BIOTIME INC Financials Mar 23 2017
BioTime, Inc.: Trading close to its 50 day moving average. Good buy? Mar 22 2017
BioTime, Inc. is trading above its 50 day moving average : BTX-US : March 22, 2017 Mar 22 2017
BioTime, Inc. :BTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
BioTime, Inc. :BTX-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017 Mar 21 2017
BioTime, Inc.: Strong price momentum but will it sustain? Mar 20 2017
BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : March 20, 2017 Mar 20 2017
BioTime to Present at Oppenheimer 27th Annual Healthcare Conference Mar 20 2017
BIOTIME INC Files SEC form 8-K, Results of Operations and Financial Condition Mar 16 2017
BioTime, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate... Mar 16 2017
Q4 2016 BioTime Inc Earnings Release - After Market Close Mar 16 2017
Data From BioTime’s OpRegen® Trial in Dry-AMD to be Presented at ARVO on May 8 Mar 15 2017
BioTime Expands OpRegen® Clinical Trial in Dry-AMD With Opening of First US Sites Mar 13 2017
BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : March 8, 2017 Mar 08 2017
BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : March 7, 2017 Mar 07 2017
BioTime, Inc. : Undervalued relative to peers, but don’t ignore the other factors Feb 27 2017
BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : February 24, 2017 Feb 24 2017
BioTime, Inc. to Announce Fourth Quarter and Fiscal 2016 Results on March 16, 2017 Feb 23 2017
BioTime Reports $56M Non-Cash Gain On Deconsolidation Feb 22 2017
BioTime (BTX) Shows Strength: Stock Adds 7.1% in Session Feb 22 2017
BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary Feb 21 2017
BIOTIME INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial... Feb 21 2017
BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing... Jan 03 2017
BioTime Achieves Patient Recruitment Milestone in Renevia Pivotal Trial Dec 14 2016
Positive Early Data From BioTime’s Renevia Pivotal Trial Presented at IFATS Meeting Nov 18 2016
BioTime, Inc. Reports Third Quarter Results and Recent Clinical Progress Nov 03 2016
BioTime Appoints Industry Veteran Jim Knight as Senior Vice President, Head of Corporate Development Oct 31 2016
BioTime, Inc. to Announce Third Quarter Results on November 3, 2016 Oct 24 2016
First Patient Cohort Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to Be Presented at... Oct 20 2016
LifeMap Solutions Joins Medidata AppConnect Partner Program to Drive mHealth Innovation Oct 18 2016
BioTime Affiliate, Asterias Biotherapeutics, Announced Positive Interim Efficacy Data From Trial in... Sep 15 2016
BioTime to Present at Two Upcoming Investor Conferences Sep 06 2016
Asterias Biotherapeutics Reports Second Quarter Results and Highlights Progress of SCiSTAR Study... Aug 15 2016
BioTime Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative... Aug 15 2016
BioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments Aug 09 2016
BioTime, Inc. to Report Second Quarter Results on August 9, 2016 Jul 27 2016
BioTime, Inc. Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option Jul 05 2016
BioTime Presents Online Resource for Applying Artificial Intelligence to Stem Cell Biology at Mensa... Jun 29 2016
BioTime, Inc. Announces Closing of Public Offering of Common Stock Jun 21 2016
BioTime, Inc. Announces Pricing of Public Offering of Common Stock Jun 16 2016
BioTime, Inc. Announces Proposed Public Offering of Common Stock Jun 15 2016
BioTime’s Subsidiary Cell Cure Neurosciences Receives DSMB Approval to Start Second Patient Cohort... Jun 13 2016
BioTime Announces $2.2 Million Grant for Further Development of Dry-AMD Program Jun 10 2016
BioTime to Present at the Jefferies 2016 Global Healthcare Conference Jun 09 2016
BioTime to Present at Two Upcoming Investor Conferences May 20 2016
BioTime Co-CEO Dr. Michael West to Present at Stem Cells in Drug Discovery 2016 in Cambridge, UK Apr 05 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)